科塞尔医疗完成近亿元B+轮融资，加速血管介入器械全领域平台化布局

Core Insights - Koser Medical Technology (Suzhou) Co., Ltd. has completed nearly 100 million yuan in B+ round financing, led by Tietou Jushi, with continued investment from Suzhou High-tech Investment and participation from Yuanyong Investment [1] - The funds will be used for core product development, global market promotion, and capacity expansion, reflecting investors' recognition of Koser Medical's rapid and high-quality development and future potential [1] Company Overview - Founded in 2013, Koser Medical has become a platform enterprise in the vascular interventional device field, with a business layout of "one core and three wings" [2] - The company has developed a one-stop treatment system for peripheral intervention, with subsidiaries focusing on cardiac electrophysiology, coronary intervention product development, and breakthrough core material technologies [2] - Koser Medical has implemented a "Local Base, Global Reach" strategy, acquiring Ireland's Micell in 2021 to gain access to extensive clinical data and special coating technologies, marking a significant step towards globalization [2] Financial and Market Position - The company has invested over 300 million yuan in R&D, building a rich technology platform with nearly 100 patents and over 40 medical device registrations, including nearly 20 international certifications [2] - Koser Medical has established a complete market, academic, and sales team, collaborating with nearly 2,000 hospitals in China [2] Investor Perspectives - Tietou Jushi emphasized the importance of Koser Medical's platform layout, international strategy, rich product pipeline, and strong market capabilities, expressing confidence in the management team's strategic vision [3] - Suzhou High-tech Investment highlighted Koser Medical's ability to meet the growing demand for vascular diagnosis and treatment, recognizing the company's innovative products and long-term competitiveness in the industry [3] - Yuanyong Investment noted the deep integration of industry, academia, and research within Koser Medical, expressing confidence in the company's potential to become a benchmark enterprise for Nanjing University alumni [4]